Table 1.
Demographics and procedural parameters for 895 ERCP procedures
| Characteristics | Number of procedures (%) |
|---|---|
| Sex | |
| Female | 461 (51.5) |
| Male | 434 (48.5) |
| Age—mean (SD) | 58.5 (18.4) |
| Disposition | |
| Outpatient | 410 (45.8) |
| Inpatient | 483 (54.1) |
| Antiplatelet or anticoagulant use | |
| Yes | 268 (29.9) |
| No | 627 (70.1) |
| Primary indication for ERCP | |
| Suspected or confirmed CBD stone(s) | 546 (61.0) |
| Suspected or confirmed CBD stricture(s) | 264 (29.5) |
| Cholangitis | 41 (4.6) |
| Other (specific indications recorded) | 44 (4.9) |
| Prior ERCP | |
| Yes | 348 (38.9) |
| No | 546 (61.0) |
| Trainee involved | |
| Yes | 514 (57.4) |
| No | 378 (42.2) |
| Rectal NSAID given for mitigation of pancreatitis | |
| Yes | 329 (36.8) |
| No | 541 (60.4) |
CBD Common bile duct; ERCP Endoscopic retrograde cholangiopancreatography; NSAID Nonsteroidal anti-inflammatory drug; SD Standard deviation.